These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 21510993)

  • 21. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.
    Piedra PA; Gaglani MJ; Kozinetz CA; Herschler GB; Fewlass C; Harvey D; Zimmerman N; Glezen WP
    Pediatrics; 2007 Sep; 120(3):e553-64. PubMed ID: 17698577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination.
    Muhamed G; Greenbaum E; Zakay-Rones Z
    Isr Med Assoc J; 2006 Mar; 8(3):155-8. PubMed ID: 16599048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influenza vaccination coverage rates in 5 European countries: a population-based cross-sectional analysis of the seasons 02/03, 03/04 and 04/05.
    Müller D; Szucs TD
    Infection; 2007 Oct; 35(5):308-19. PubMed ID: 17885730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Barriers to and facilitators of child influenza vaccine - perspectives from parents, teens, marketing and healthcare professionals.
    Bhat-Schelbert K; Lin CJ; Matambanadzo A; Hannibal K; Nowalk MP; Zimmerman RK
    Vaccine; 2012 Mar; 30(14):2448-52. PubMed ID: 22300721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing protection against influenza in children eligible for the vaccine for children program.
    Hull HF; O'Connor H
    Pediatr Infect Dis J; 2010 Oct; 29(10):910-4. PubMed ID: 20431426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009-2010 season.
    Tennis P; Toback SL; Andrews EB; McQuay LJ; Ambrose CS
    Vaccine; 2012 Sep; 30(42):6099-102. PubMed ID: 22841479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influenza vaccination coverage rates in five European countries-a population-based cross-sectional analysis of two consecutive influenza seasons.
    Szucs TD; Müller D
    Vaccine; 2005 Oct; 23(43):5055-63. PubMed ID: 16046035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influenza vaccination attitudes and practices among US registered nurses.
    Clark SJ; Cowan AE; Wortley PM
    Am J Infect Control; 2009 Sep; 37(7):551-6. PubMed ID: 19556035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
    Belshe RB; Mendelman PM; Treanor J; King J; Gruber WC; Piedra P; Bernstein DI; Hayden FG; Kotloff K; Zangwill K; Iacuzio D; Wolff M
    N Engl J Med; 1998 May; 338(20):1405-12. PubMed ID: 9580647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parents' decision-making regarding vaccinating their children against influenza: A web-based survey.
    Flood EM; Rousculp MD; Ryan KJ; Beusterien KM; Divino VM; Toback SL; Sasané M; Block SL; Hall MC; Mahadevia PJ
    Clin Ther; 2010 Aug; 32(8):1448-67. PubMed ID: 20728759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Background paper to the recommendation for the preferential use of live-attenuated influenza vaccine in children aged 2-6 years in Germany.
    Falkenhorst G; Harder T; Remschmidt C; Terhardt M; Zepp F; Ledig T; Wicker S; Keller-Stanislawski B; Mertens T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1557-64. PubMed ID: 24170085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age.
    Vesikari T; Karvonen A; Smith HM; Dunning A; Razmpour A; Saville MK; Gruber WC; Forrest BD
    Pediatrics; 2008 Mar; 121(3):e568-73. PubMed ID: 18299305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trivalent intranasal influenza vaccine, live.
    McCarthy MW; Kockler DR
    Ann Pharmacother; 2004 Dec; 38(12):2086-93. PubMed ID: 15494383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse events associated with intranasal influenza vaccine in the United States.
    Vasu N; Ghaffari G; Craig ET; Craig TJ
    Ther Adv Respir Dis; 2008 Aug; 2(4):193-8. PubMed ID: 19124371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccination of children with a live-attenuated, intranasal influenza vaccine - analysis and evaluation through a Health Technology Assessment.
    Andersohn F; Bornemann R; Damm O; Frank M; Mittendorf T; Theidel U
    GMS Health Technol Assess; 2014; 10():Doc03. PubMed ID: 25371764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seasonal influenza vaccination coverage among local health department personnel in North Carolina, 2007-2008.
    Kent JN; Lea CS; Fang X; Novick LF; Morgan J
    Am J Prev Med; 2010 Jul; 39(1):74-7. PubMed ID: 20537842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.
    McMahon AW; Iskander J; Haber P; Chang S; Woo EJ; Braun MM; Ball R
    Pediatrics; 2005 Feb; 115(2):453-60. PubMed ID: 15687455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of influenza on young children and the shaping of United States influenza vaccine policy.
    Terebuh P; Uyeki T; Fukuda K
    Pediatr Infect Dis J; 2003 Oct; 22(10 Suppl):S231-5. PubMed ID: 14551482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of intranasal virosomal influenza vaccine in the prevention of recurrent acute otitis media in children.
    Marchisio P; Cavagna R; Maspes B; Gironi S; Esposito S; Lambertini L; Massimini A; Herzog C; Principi N
    Clin Infect Dis; 2002 Jul; 35(2):168-74. PubMed ID: 12087523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influenza vaccination coverage rates in Germany a population-based cross-sectional analysis of the seasons 2002/2003 and 2003/2004.
    Müller D; Wutzler P; Szucs TD
    Med Klin (Munich); 2005 Jan; 100(1):6-13. PubMed ID: 15654537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.